Open AccessComparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections
Author(s) -
Marin L. Schweizer,
Kelly Richardson,
Mary Vaughan-Sarrazin,
Michihiko Goto,
Daniel Livorsi,
Rajeshwari Nair,
Bruce Alexander,
Brice Beck,
Michael P. Jones,
Mireia Puig-Asensio,
Daniel Suh,
Michael Ohl,
Eli N. Perencevich
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1572
Subject(s) - daptomycin , medicine , vancomycin , methicillin resistant staphylococcus aureus , staphylococcus aureus , bacteremia , staphylococcal infections , confidence interval , surgery , antibiotics , microbiology and biotechnology , biology , bacteria , genetics
Patients with methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA BSI) usually receive initial treatment with vancomycin but may be switched to daptomycin for definitive therapy, especially if treatment failure is suspected. Our objective was to evaluate the effectiveness of switching from vancomycin to daptomycin compared with remaining on vancomycin among patients with MRSA BSI.